From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE

Clinical and Translational Immunology

Volumn 4, Issue 4, 2015, Pages

  Coler, Rhea N ^a   Duthie, Malcolm S ^a   Hofmeyer, Kimberly A ^a   Guderian, Jeffery ^a   Jayashankar, Lakshmi ^a   Vergara, Julie ^a   Rolf, Tom ^a   Misquith, Ayesha ^a   Laurance, John D ^a   Raman, Vanitha S ^a   Bailor, H Remy ^a   Cauwelaert, Natasha Dubois ^a   Reed, Steven J ^a   Vallur, Aarthy ^a   Favila, Michelle ^a   Orr, Mark T ^a   Ashman, Jill ^a   Ghosh, Prakash ^b   Mondal, Dinesh ^b   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE PHOSPHATE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; LEISHMANIA VACCINE; LEISHMANIA VACCINE LEISH F3 GLA SE; METHYLTRANSFERASE; NUCLEOSIDASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CD4+ T LYMPHOCYTE; CHILL; CONGENITAL MALFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE REACTION; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MAJOR HISTOCOMPATIBILITY COMPLEX; MALAISE; MOUSE; MYALGIA; NONHUMAN; NORMAL HUMAN; PARASITE LOAD; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TH1 CELL; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION; VISCERAL LEISHMANIASIS;

EID: 84939489959     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2015.6     Document Type: Article

References (84)

1. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 2009; 16: 599–614.
2. World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser 2010; 793: 1–158.
3. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012; 7: e35671.
4. Joshi AB, Banjara MR, Pokhrel S, Jimba M, Singhasivanon P, Ashford RW. Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities. Kathmandu Univ Med J (KUMJ) 2006; 4: 488–496.
5. Kumar V, Kesari S, Dinesh DS, Tiwari AK, Kumar AJ, Kumar R et al. A report on the indoor residual spraying (IRS) in the control of Phlebotomus argentipes, the vector of visceral leishmaniasis in Bihar (India): an initiative towards total elimination targeting 2015 (Series-1). J Vector Borne Dis 2009; 46: 225–229.
6. Bhattacharya SK, Sur D, Sinha PK, Karbwang J. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable. Indian J Med Res 2006; 123: 195–196.
7. Das VN, Dinesh DS, Verma N, Kar SK. A case report on self-cure of visceral leishmaniasis. J Commun Dis 2002; 34: 302–303.
8. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a visceral leishmaniasis vaccine in Bihar state, India. Am J Trop Med Hyg 2012; 86: 417–425.
9. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985; 76: 2066–2069.
10. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144–4148.
11. Kaye PM, Aebischer T. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin Microbiol Infect 2011; 17: 1462–1470.
12. Kumar R, Nylen S. Immunobiology of visceral leishmaniasis. Front Immunol 2012; 3: 1–10.
13. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007; 204: 805–817.
14. Goto Y, Coler RN, Guderian J, Mohamath R, Reed SG. Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun 2006; 74: 3939–3945.
15. Paraguai de Souza E, Bernardo RR, Palatnik M, Palatnik de Sousa CB. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 2001; 19: 3104–3115.
16. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 2005; 73: 812–819.
17. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 2002; 20: 3277–3284.
18. Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007; 25: 7450–7458.
19. Goto Y, Bhatia A, Raman VS, Vidal SE, Bertholet S, Coler RN et al. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine 2009; 27: 2884–2890.
20. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011; 6: e16333.
21. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B 2010; 75: 123–132.
22. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2: 53ra74.
23. Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 2011; 3: 93ra69.
24. Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 2011; 29: 644–649.
25. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009; 27: 7036–7045.
26. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf 2008; 65: 98–105.
27. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011; 29: 9563–9572.
28. Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 2010; 53: 303–321.
29. Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PLoS ONE 2014; 9: e88979.
30. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP et al. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS ONE 2012; 7: e41144.
31. Schneider LP, Schoonderwoerd AJ, Moutaftsi M, Howard RF, Reed SG, de Jong EC et al. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 2012; 30: 4216–4224.
32. Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 2012; 205: 466–473.
33. Zhang W, Ahmad G, Le L, Rojo JU, Karmakar S, Tillery KA et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res 2014; 113: 2239–2250.
34. Karmakar S, Zhang W, Ahmad G, Torben W, Alam MU, Le L et al. Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine 2014; 32: 1296–1303.
35. Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, Picone AF et al. KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol 2011; 18: 1118–1124.
36. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19: 1597–1608.
37. Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P et al. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 2013; 31: 5760–5765.
38. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843–850.
39. Li Pira G, Ivaldi F, Moretti P, Manca F. High throughput T epitope mapping and vaccine development. J Biomed Biotechnol 2010; 2010: 325720.
40. Hoffmeister B, Kiecker F, Tesfa L, Volk HD, Picker LJ, Kern F. Mapping T cell epitopes by flow cytometry. Methods 2003; 29: 270–281.
41. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H. de Vries JE. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991; 173: 747–750.
42. Kitani A, Strober W. Regulation of C gamma subclass germ-line transcripts in human peripheral blood B cells. J Immunol 1993; 151: 3478–3488.
43. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104–1107.
44. Vanlerberghe V, Diap G, Guerin PJ, Meheus F, Gerstl S, Van der Stuyft P et al. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Health 2007; 12: 274–283.
45. Berman J. ABLE: a new and improved amphotericin B for visceral leishmaniasis? Am J Trop Med Hyg 2009; 80: 689–690.
46. Stager S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000; 165: 7064–7071.
47. Ghosh A, Zhang WW, Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001; 20: 59–66.
48. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005; 174: 7160–7171.
49. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006; 24: 2169–2175.
50. Duthie MS, Raman VS, Piazza FM, Reed SG. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012; 30: 134–141.
51. Singh B, Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012; 30: 3834–3842.
52. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001; 69: 4719–4725.
53. Sukumaran B, Tewary P, Saxena S, Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 2003; 21: 1292–1299.
54. Gupta R, Kushawaha PK, Tripathi CD, Sundar S, Dube A. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int J Parasitol 2012; 42: 429–435.
55. Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S et al. Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis. PLoS ONE 2012; 7: e45766.
56. Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral leishmaniasis. PLoS ONE 2012; 7: e35670.
57. + T cells. Infect Immun 2007; 75: 4648–4654.
58. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002; 70: 4215–4225.
59. Wang Y, Chen Y, Xin L, Beverley SM, Carlsen ED, Popov V et al. Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes. Infect Immun 2011; 79: 1124–1133.
60. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 2009; 106: 2301–2306.
61. Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009; 27: 3063–3071.
62. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001; 69: 2773–2778.
63. Wang B, Henao-Tamayo M, Harton M, Ordway D, Shanley C, Basaraba RJ et al. A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol 2007; 14: 902–906.
64. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174: 6332–6339.
65. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17: 189–194.
66. Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS ONE 2013; 8: e80579.
67. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172: 7618–7628.
68. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011; 29: 3531–3537.
69. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, Coler RN et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010; 28: 7427–7435.
70. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010; 28: 6581–6587.
71. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, Alves FP et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009; 28: 329–337.
72. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 2009; 4: e6465.
73. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccines 2009; 5: 475–482.
74. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000; 68: 6289–6293.
75. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 1989; 143: 4244–4249.
76. Murray HW, Miralles GD, Stoeckle MY, McDermott DF. Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol 1993; 151: 929–938.
77. Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990; 145: 4306–4310.
78. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205: 3119–3131.
79. Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLoS Negl Trop Dis 2012; 6: e1874.
80. Duthie MS, Goto W, Ireton GC, Reece ST, Cardoso LP, Martelli CM et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol 2007; 14: 1400–1408.
81. Duthie MS, Goto W, Ireton GC, Reece ST, Sampaio LH, Grassi AB et al. Antigen-specific T-cell responses of leprosy patients. Clin Vaccine Immunol 2008; 15: 1659–1665.
82. Vallur AC, Duthie MS, Reinhart C, Tutterrow Y, Hamano S, Bhaskar KR et al. Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasis. Clin Microbiol Infect 2014; 20: 374–383.
83. Rolao N, Cortes S, Rodrigues OR, Campino L. Quantification of Leishmania infantum parasites in tissue biopsies by real-time polymerase chain reaction and polymerase chain reaction-enzyme-linked immunosorbent assay. J Parasitol 2004; 90: 1150–1154.
84. ICSSC. Monitoring and Reporting Adverse Events: Appendix VII www Resource Links 2003. Available at: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%20final.pdf (updated 6 February 2003; last accessed 6 April 2009).